ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, Reata Pharmaceuticals, Inc. (RETA) shows an Average True Range (ATR) of N/A and an Enterprise Value of N/A. Its average trading volume over the past 3 months is N/A, indicating liquidity. These fundamental metrics provide insight into RETA's underlying financial health and market activity.
Reata Pharmaceuticals, Inc. (RETA) technical indicators as of August 1, 2025: the SMA 20 is N/A, SMA 50 at N/A, and SMA 200 at N/A. The RSI 14 value is N/A, suggesting its current momentum. These technical analysis signals help assess RETA's price trends and potential future movements.
Reata Pharmaceuticals, Inc. (RETA) stock performance overview as of August 1, 2025: The 52-week high is N/A (currently N/A below), and the 52-week low is N/A (currently N/A above). Over the past year, RETA's performance is -86.82%, compared to the S&P 500's 14.84% change.
According to market data, Reata Pharmaceuticals, Inc. (RETA) stock's recent performance metrics show that over the last month, RETA is -1.91%, with a Year-to-Date (YTD) performance of -76.64%. Over the past year, the stock has seen a -86.82% change. These figures summarize RETA's price movements across various periods, reflecting its historical returns.
According to current financial data, RETA stock's P/E (TTM) ratio is -20.07, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.24. Key valuation ratios for RETA, including P/S (2963.20), P/B (-95.29), and P/FCF (-31.64), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.